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Summary 
Human immunodeficiency  virus (HIV) induces strong responses from human histocompatibility 
leukocyte antigen (HLA) class I-restricted cytotoxic T lymphocytes (CTL). In a previous report 
we identified an immunodominant region (amino acids 73-144) in the NEF protein that was 
recognized by CD8 + class I-restricted CTL of most asymptomatic individuals. Analysis of the 
73-144 region by peptide sensitization  experiments  using overlapping peptides corresponding 
to the LAI isolate identified the peptide sequences located between residues 73 and 82 or 84 
and 92 and the peptide sequence between residues 134 and 144 as cognate peptides for HLA-A11- 
and HLA-B18-restricted epitopes, respectively. This report describes the variable demonstrable 
reactivities of CTL obtained from HLA-A11 or HLA-B18 seropositive, asymptomatic patients 
who all had a response to the virus NEF protein, but who did not always recognize appropriate 
cognate peptides. The high mutation rate of HIV probably facilitates the selection of mutants 
that can avoid the cellular immune response. We therefore analyzed the variability of these epitopes 
restricted by HLA-A11 and HLA-B18. We sequenced several viral isolates from HLA-All and 
HLA-B18 donors who recognized certain HLA-peptide complexes and from those who did not. 
A CTL sensitization  assay was used to show that some mutations led to a great reduction in 
CTL  activity in vitro.  This might be due to failure of the mutated epitope  to bind major 
histocompatibility  complex class I molecule.  A simple assay was used to detect peptides that 
promoted the assembly of class I molecules. Some of these mutations at major anchor positions 
prevented HLA-A11/peptide binding, and consequently impaired recognition of the HLA-peptide 
complex by the T  cell receptor. 
I 
ndividuals infected with HIV-1 generate a great diversity 
￿9  of CTL. These CTL are directed against several structural 
and regulatory HIV-1 proteins (1) and each protein can have 
multiple T cell epitopes (2-5). The rapid elimination of in- 
fected cells by CTL directed against proteins synthesized early 
in infection is an important defense against viral infection. 
CTL directed against the early-expressed  NEF protein of HIV 
could provide protection in vivo by eliminating virus-infected 
cells before there is substantial release of virus particles. We 
have previously identified an immunodominant region in the 
central portion of the NEF protein (residues 73-144) that is 
recognized by most of the patients producing a CTL response 
to NEF in association with several HLA class I molecules 
(2, 3). This result pointed out the widespread recognition 
of conserved epitopes in the NEF protein. We used a peptide 
sensitization assay to identify and describe three peptide se- 
quences within this region; two are cognate peptides for HLA- 
All-restricted epitopes (residues  73-82[QVPLRPMTYK] and 
residues 84-92[AVDLSHFLK]), and the third for HLA-B18 
(residues 134-144[RYPLTFGWCYK]) (Culmann-Penciolelli, 
B., S. Lamhamedi-Cherradi,  I. Couillin, N. Guegan, J.  P. 
Levy, J. G. Guillet,  and E. Gomard, manuscript submitted 
for publication).  We have now obtained  CTL from a geo- 
graphically-defined  cohort  of  HLA-A11  and  HLA-B18 
seropositive asymptomatic patients and tested their reactivi- 
ties to these peptides.  The CTL from certain of these pa- 
tients did not recognize the appropriate cognate peptide(s). 
The high mutation rate of HIV could play a major part in 
selecting mutants having hidden functional epitopes, as re- 
cently described for GAG and ENV proteins of HIV (6-8). 
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of a CTL response to the NEF protein epitopes is due to 
viral mutation. 
Materials and Methods 
LymFhocytes.  PBMC  from asymptomatic HIV-1  seropositive 
donors were isolated in a density gradient and frozen in liquid 
nitrogen. HLA serotyping was performed by the tissue-typing lab- 
oratory of the  H6pital  Saint-Louis  (Paris,  France):  W8  [HLA- 
All/26, B7/37, C6/7]; W13 [HLA-A25/32, B18/-, C8/-]; W19 
[HLA-A2/19.2, B18/62, C5/-]; W24 [HLA-A2/11, B18/-, C7/-]; 
and W44 [HLA-A2/-, B18/44,  C5/-]. 
Cytotoxic T Celt Assays.  Polyclonal anti-HIV cell lines were es- 
tablished in culture for 2-3 wk using PBMC (106/ml) with au- 
tologous PHA-activated lymphocytes (2  x  10S/ml) as previously 
described (3). CTL activity was assayed by a chromium release test 
(CRT), using EBV-transformed lymphoblastoid cell lines as target 
cells. They were prepared as previously described (2), either by in- 
fection with wild-type vaccinia virus VAC-WT or HIV-1/LAI nef 
recombinant  vaccinia  virus  VAC-NEF  (Transg~ne,  Strasbourg, 
France),  or by incubation with synthetic peptides corresponding 
to the HIV-1/LAI NEF sequence or to mutated sequences (Neo- 
system, Strasbourg, France). For peptide titration experiments, target 
cells were incubated with 10-fold serial dilutions of mutated or LAI 
reference peptides for 1 h (final concentrations: 0.003-3 #g/ml). 
Preparation of DNA.  PBMC pellets were suspended in an equal 
volume of buffer (50 mM Tris, pH 8,  500 mM NaC1,  20 mM 
EDTA), and the cells were lysed by adding one volume of buffer 
containing 1% SDS. The lysates were treated with RNase A (0.1 
mg/ml, 30 rain at 37~  and proteinase K (0.4 mg/ml, overnight 
at 37~  and DNA isolated by phenol/chloroform extraction and 
ethanol precipitation. 
PCR, Clonin~ and Sequencing of NEF Protein.  The PCR reac- 
tions were carried out in a 100-#1 reaction mixture containing 10 
mM Tris-HCl, pH 8.3, 50 mM KC1, 2 mM MgC12, 0.2 mM each 
dNTP, 0.4/~g of each primer, 1.5 U 7~q polymerase (Perkin Elmer 
Cetus, Norwalk, CT), and 2/~g PBMC cell DNA. The primers 
were NEF5S 5'GTGTCGACAAGAAT(N)AGACA~CTT(R)G 
AAAG-3' (sense; Sail site underlined) and NEF3R 5'ACGAATTC 
TGGAAAGTCCCCAGCGGAAAGT-3' (antisense, EcolLI site un- 
derlined) corresponding to nucleotides 8352-8375  and 9031-9052 
of the HIV-1/LAI sequence,  respectively.  Samples underwent 40 
amplification cycles. Each cycle consisted of three steps: denatura- 
tion at 92~  for 1.5 min, annealing of primers at 58~  for 1.5 
min, and extension at 72~  for 1.5 rain. In the first cycle, sample 
were denatured at 94~  for 4 rain, and in the last cycle, the exten- 
sion step was at 72~  for 5 rain. Amplified products were digested 
with restriction enzymes (SalI and EcoRI) purified, and cloned in 
a M13mp18 vector digested by SalI and EcoRI. For each patient, 
the whole nefgene for different clones was sequenced (model 373A 
sequencer;  Applied Biosystems,  Inc., Foster City, CA). 
Detection of HLA-AII Assembly by ELISA.  The assay (9) used 
T2 cells expressing HLA-A11 molecules  (10) (a gift of Dr. M. G. 
Masucci,  Karolinska  Institute, Stockholm, Sweden).  Briefly, ali- 
quots of 0.8  x  106 T2-A11 cells were lysed in 64/~1 10 mM Tris- 
buffered saline, pH 7.5, containing 1% NP-40, protease inhibitors, 
and  1 /~M  exogenous peptide.  The mixture  was  incubated  in 
microfuge tubes (model 0030102.002;  Eppendorf, Hamburg, Ger- 
many) at 37~  for 30 min, and HLA-A11 assembly was detected 
on microtiter plates coated with Ig A11.1M (11) (1/~g in 100/~1 
PBS per well).  The equivalent of 4  x  10  s cells in 100/~1 medium 
per well was incubated with Ig for 20 h at 4~  It was then in- 
cubated with the second Ab, an anti-~/2 microglobulin, M28 Ig 
(12), labeled with biotin (2/~g/ml) for 1 h at 37~  Reaction prod- 
ucts were detected by incubation with ExtrAvidin-alkaline  phos- 
phatase (E-2636; Sigma Chemical Co., St. Louis, MO) for 45 rain 
at  22~  Alkaline  phosphatase  activity was  detected with  the 
p-nitrophenyl phosphate disodium hexahydrate  as substrate (104- 
105; Sigma Chemical Co.) and the resulting absorbance was mea- 
sured at 405-492 nm. 
Results and Discussion 
We have attempted to obtain further insight into the mech- 
anisms by which persistant virus evades CTL.  The nucleo- 
tidic sequences of the nefgenes of several HIV-1 clones from 
donors whose CTL recognized the cognate peptides for HLA- 
All or HLA-B18-restricted epitopes in the immunodominant 
region of NEF residues 73-144 (2-4) and from donors whose 
CTL did not recognize one or more of these peptides were 
determined.  The deduced amino acid sequences were com- 
pared with that of the LAI isolate used to define the refer- 
ence NEF  epitopes. 
As shown in Fig. 1, CTL from donors W8 and W24 rec- 
ognized two distinct epitopes located in the central region 
of the NEF protein in association with the HLA-All mole- 
cule. Peptide 84-92 was recognized by donor W8,  but not 
peptide 73-82, whereas the reverse occurred with donor W24. 
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Figure 1.  Cytotoxic activity  of CTL prepared  from the 
PBMC of W8 and W24 HLA-A11 donors against two 
HLA-A11-restficted  epitopes  in the central region of NEF 
protein.  Effector cells were prepared as  described in 
Materials and Methods. Target  cells shared only the HLA- 
All molecule  with effector  cells, and were either infected 
with VAC-WT or VAC-NEF, or incubated  with synthetic 
peptides NEF 73-82 and NEF 84-92. 
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Figure  2.  Mutations in the putative  anchorage  residues (in italic and 
bold type) or in flanking residues of two HLA-All-restricted NEF epi- 
topes from different isolates from HIV-infected donors W8 and W24. The 
LAI peptides recognized by CTL from these donors (see Fig. 1) are shown 
in gray boxes. 
The differences between these two donors are not related to 
subtypes of HLA-All molecules, as defined by cellular tests 
(13), since the B-EBV ceils of donors who did not recognize 
one of the cognate peptides can present this peptide to CTL 
from donors whose CTL recognize the nonmutated epitope. 
All 13 virus isolates examined from donors W8 and W24 
had mutations in position 2 (Val to Leu, Phe, or Arg) of pep- 
tide 84-92, and one isolate recovered from donor W24 also 
had a Lys for Arg substitution in position 9 (Fig. 2). It is 
more than likely that the Val in position 2 and Lys in posi- 
tion 9 are the anchoring residues for HLA-All, since they 
are also found in other HLA-All-restricted epitopes, such 
as peptide NEF 73-82 and peptide  416-424 of the nuclear 
antigen 4 of EBV (10). We tested to see whether the corre- 
sponding mutated peptides could sensitize target cells to CTL 
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Titration of LAI reference peptides or mutated peptides cot- 
responding to the HLA-All-restricted 84-92 epitopic region. Effector cells 
were CTL generated  from the PBMC of donor W8 and tested against 
autologous  target cells. The E/T cell ratio was 230:1. 
lysis. The Yal to Leu change in position 2 of the W8 isolate 
did not influence recognition of the 84-92 epitope by HLA- 
All-restricted CTL. In contrast,  the other mutations in the 
W24 isolates all affected the peptide  sensitization of target 
cells to lysis by CTL from donor W8 (Fig. 3). Peptide titra- 
tion experiments demonstrated that cognate peptide caused 
sensitization at extremely low concentrations,  whereas pep- 
tides containing the putative  mutations in the anchoring 
residues (Val to Arg in position 2, or Val to Phe in position 
2 together with a mutation Lys to Arg in position 9) were 
required in correspondingly higher concentrations.  We also 
used a simple assay  to detect peptides promoting the assembly 
of HLA class I molecule in T2-All cells in order to deter- 
mine whether mutations in the epitopic  region prevented 
binding of the corresponding peptide to HLA molecules or 
affected the direct recognition by the TCR. Synthetic pep- 
tides corresponding to these mutations did not promote HLA- 
All  assembly (Fig. 4),  These results  are consistent  with 
previous observations that a peptide of a nucleoprotein from 
influenza virus with an Arg in position 2 did not bind to 
HLA-A3, a molecule very similar to HLA-A11 in most of 
the regions responsible for peptide binding specificity (14), 
and a Lys to Thr substitution in position 9 impaired HLA- 
All binding of EBV-derived  epitopes (15). These results there- 
fore show that W24 isolates contain mutations in residues 
that are required for effective peptide  binding. 
The recognition of the 73-82 region by CTL from donor 
W24 (Fig. 1), is probably due to the presence of the wild- 
type sequence in the isolates from this donor (clone 24.2, 
Fig. 2), since substitutions  corresponding to the mutations 
identified in the W24 isolates (Tyr to Ser in position  9 and 
Lys to Arg in position  10) resulted in a very low binding 
to HLA-All (Fig. 4). 
Mutations in anchoring residues might not be the only 
mechanism by which mutants evade the HLA-All-restricted 
CTL response. The regions corresponding to the NEF epi- 
tope 73-82 were entirely conserved in nine isolates from donor 
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Figure  4.  Assembly of HLA-All molecules in the presence of Nef pep- 
tides. Peptides (1 #M) were incubated in T2-All cells lysates as described 
in Materials and Methods.  ELISA results are expressed as OD at 405/492 
nm. The spontaneous assembly obtained with T2-A11 lysate without adding 
exogenous peptide was subtracted.  It was 0.310  _+ 0.025 (mean of several 
experiments) after incubation with alkaline phosphatase substrate for 1 h. 
The assembly ratio was 2.56  _+  0.20 for peptide Nef 73-82 and 2.19  +_ 
0.36 for peptide Nef 84-92.  Mutated residues in the peptide  sequences 
are indicated  in bold type. 
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Figure  5.  Cytotoxic activity of CTL prepared  from 
donors W13, W19, W24, and W44 against HLA-B18-re- 
stricted NEF 134-144 peptide. Effector cells were prepared 
as described in Materials and Methods. Target cells shared 
only the HLA-B18 molecule with effector cells, and were 
either infected with VAC-WT or VAC-NEF, or incubated 
with NEF 134-144 synthetic peptides. NEF-specific CTL 
from donor W19 recognized another epitope, NEF 117- 
127, in association  with HLA-B62  (data not shown). 
W8 who did not recognize this epitope, whereas there were 
mutations  in the flanking positions  71 (Thr to Arg or Lys) 
and 83 (Ata to Gly) (Pig. 2). This suggests  that mutations 
in flanking regions may hinder antigen processing, as has been 
described for another viral system (16). Such mutation could 
affect the stoichiometry  of a defined immunodominant  epi- 
tope, which may explain the presence of another HLA-A11-re- 
stricted epitope  in these isolates. 
The mechanism by which the mutants isolated from donor 
W19 evade HLA-B18-restricted CTL responses, whereas iso- 
lates from three other HLA-B18  donors do not (Fig. 5), is 
less clear. All three W19 isolates have a Thr to Cys mutation 
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Figure  6.  Mutations in the HLA-B18-restricted  NEF 134-144 epitope 
in isolates from four donors. The dones sequenced from each HIV-infected 
donor represent  different  isolates and are compared  to the reference se- 
quence of the LAI isolate. The LAI peptide recognized by CTL from each 
donor (see Fig.  5) is shown in gray boxes. 
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Figure  7.  Titration of LAI reference peptide or mutated peptide corre- 
sponding to the HLA-B18-restricted NEF 134-144 epitopic region. Effector 
cells were obtained from donor W44, and were tested against HLA-B18 
target cells (W19 B-EBV). The E/T cell ratio  was  100:1. 
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epitope 134-144 for HLA-B18 (Fig.  6).  The corresponding 
mutated peptide did not sensitize target cells to lysis by CTL 
from W19  (Fig.  5).  The  CTL from donor W44,  which 
responded to the standard HIV-1/LAI NEF peptide (amino 
acids  134-144) recognized this sequence  even when it was 
presented on B-EBV cells from donor W19, that had the same 
restriction element. But they recognized the mutant peptide 
poorly unless very high peptide concentrations were used (Fig. 
7). It is not yet possible to determine whether cysteine 138 
induces a lower antigenicity for CTL, or weaker binding to 
the groove of HLA-B18 molecule, since the anchoring residues 
for HLA-B18 molecules have yet to be determined and T2- 
B18 cells are not available for binding experiments. We have 
also been unable to generate mutated peptide-induced CTL 
lines using W19 PBMC, although this approach was used 
to determine nondominant epitopes (3,  17) which may be 
limited by the TCR repertoire. 
These results show that the mechanism for generating CTL 
escape  mutants  is  complex.  Mutations  were  found  that 
influence the avidity of the peptide for HLA molecules. Other 
mutations probably influence antigen processing,  and/or rec- 
ognition of the HLA-peptide complex by the TCR. Some 
mutations may also induce specific T cells to anergy (18, 19). 
These HIV mutants may persist  in a population. Tests on 
antigenicity of the reference NEF/LAI isolate carried out in 
Paris between 1987 and 1993, show a marked decrease in its 
ability to induce recall CTL responses  (results  not shown). 
In summary, selection pressure  may result in mutations in 
epitopes of the NEF protein that are important for efficient 
CTL recognition, and these may, in turn, facilitate virus per- 
sistence. 
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